Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Siemens Healthineers AG is a leading medical technology company specializing in innovative healthcare equipment, solutions, and services. It provides advanced technologies in diagnostic and therapeutic imaging, laboratory diagnostics, molecular medicine, cancer care, minimally invasive therapies, and digital health services, augmented by artificial intelligence and healthcare IT. The company offers a comprehensive portfolio covering the complete care continuum, from in-vitro diagnostics and best-in-class imaging to precision therapy, patient twinning for personalized care, and managed services. Key areas include imaging, diagnostics, advanced therapies like interventional oncology and robotics, and the Varian segment for radiation oncology. Siemens Healthineers AG supports healthcare providers worldwide in addressing major diseases such as cancer, cardiovascular conditions, stroke, and neurodegenerative disorders, while promoting value-based care, operational efficiencies, and sustainable access to high-quality treatment. With direct presence in over 70 countries, it tailors solutions to local needs, enabling clinical decision-making and better patient outcomes. Founded in 2016 and headquartered in Erlangen, Germany, it plays a pivotal role in the global medtech industry.
€34.23
€0.20 (-0.58%)
EOD Jun 19, 2026 · Twelve Data
12.56% operating margin is respectable but not wide. ROIC at 11.54%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 3.2%, steady but not accelerating.
Even for strong businesses, today's 18x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
17.7x earnings, 12.5x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€23.38B
▲ +3.2% YoY
Net Income (TTM)
€2.19B
▲ +28.5% YoY
Op. Margin
13.77%
▲ +2.7pp YoY
ROIC
11.54%
▲ +3.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€3.08B
▲ +66.3% YoY
Op. Cash Flow (TTM)
€3.14B
▲ +69.9% YoY
Net Debt
-€2.00B
Net Cash Position
Cash & Equiv.
€2.77B
3Y CAGR: +7.5%
3Y CAGR: -1.9%
Continue Research